Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz

Medientyp: E-Artikel
Titel: Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz
Beteiligte: van Leth, Frank; Conway, Brian; Laplumé, Hector; Martin, Des; Fisher, Martin; Jelaska, Ante; Wit, Ferdinand W; Lange, Joep MA; Laplumé, H; Lasala, MB; Losso, MH; Bogdanowicz, E; Lattes, R; Krolewiecki, A; Zala, C; Orcese, C; Terlizzi, S; Duran, A; Ebensrteijn, J; Bloch, M; Russell, O; Russell, DB; Roth, NR; Eu, B; [...]
Erschienen: SAGE Publications, 2004
Erschienen in: Antiviral Therapy
Sprache: Englisch
DOI: 10.1177/135965350400900512
ISSN: 1359-6535; 2040-2058
Schlagwörter: Infectious Diseases ; Pharmacology (medical) ; Pharmacology
Entstehung:
Anmerkungen:
Beschreibung: <jats:sec><jats:title>Objective</jats:title><jats:p> To assess whether differences in safety profiles between nevirapine (NVP) and efavirenz (EFV), as observed in the 2NN study, translated into differences in ‘health related quality of life’ (HRQoL). </jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p> A sub-study of the 2NN study, with antiretro-viral-naive patients randomly allocated to NVP (once or twice daily), EFV or NVP+EFV, in addition to stavudine and lamivudine. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> Comparing differences in changes of HRQoL over 48 weeks as measured with the Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaire, using analysis of variance. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> The 2NN study enrolled 1216 patients. No validated questionnaires were available for 244 patients, and 55 patients had no HRQoL data at all, leaving 917 patients eligible for this sub-study. A total of 471 (51%) had HRQoL measurements both at baseline and week 48. The majority (69%) of patients without HRQoL measurements did, however, complete the study. The change in the physical health score (PHS) was 3.9 for NVP, 3.4 for EFV and 2.4 for NVP+EFV ( P=0.712). For the mental health score (MHS) these values were 6.1, 7.0 and 3.9, respectively ( P=0.098). A baseline plasma HIV-1 RNA concentration (pVL) ≥100 000 copies/ml and a decline in pVL (per log<jats:sub>10</jats:sub>) were independently associated with an increase of PHS. An increase of MHS was only associated with pVL decline. Patients experiencing an adverse event during follow-up had a comparable change in PHS but a significantly smaller change in MHS, compared with those without an adverse event. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> First-line ART containing NVP and/or EFV leads to an improvement in HRQoL. The gain in HRQoL was similar for NVP and EFV, but slightly lower for the combination of these drugs. </jats:p></jats:sec>
Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: